Experience in Course of Anti-IgE Therapy of Bronchial Asthma in Children

Abstract

The results of the clinical approbation of Patient-specific therapy of bronchial asthma in children using the course method of application of the monoclonal antibodies (anti-IgE-therapy) by the Ministry of Health are summarized in order to assess the effect of this type of treatment on the disease exacerbation rate, including those associated with the seasonal acute respiratory infections. The conclusion was made regarding the high clinical efficiency in relation to all parameters studied and safety of this type of the treatment. It was determined that the monitoring of the level of specific IgE receptors on basophils using the cytoflowmetry method, which is concomitant to anti-IgE therapy, makes it possible to predict the efficiency and individual duration of anti-IgE therapy for uncontrolled atopic bronchial asthma in children.